Cabaletta Bio

Steven Nichtberger, M.D., President, CEO and Co-Founder
Philadelphia, PA
(NASDAQ: CABA)
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T-cell therapies for patients with B-cell-mediated autoimmune diseases. The CABA (Cabaletta Approach to selective B-cell Ablation) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR (Chimeric AutoAntibody Receptor) T-cells that are designed to selectively bind and eliminate B-cells that express disease-causing autoantibodies while sparing normal B-cells. CAAR T-cells were designed based on chimeric antigen receptor, or CAR, T-cell technology that is clinically validated and commercially approved to treat B-cell cancers. Our lead product candidate, DSG3-CAART, is entering clinical development as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B-cell-mediated autoimmune disease. Our lead preclinical product candidate, MuSK-CAART, has entered IND-enabling studies, and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. Several undisclosed programs are also in development.
www.cabalettabio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions